Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

242
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
242
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

717
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
717
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

631
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
631
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.3K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.3K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

456
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
456
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Culmerciclib: First Approval.

Drugs·2026
Same author

Plozasiran: First Approval.

Drugs·2026
Same author

Puzolcabtagene Autoleucel: Pediatric First Approval.

Paediatric drugs·2026
Same author

Donidalorsen: First Approval.

Drugs·2025
Same author

Viloxazine Extended-Release: A Review in Attention-Deficit/Hyperactivity Disorder in Adults.

CNS drugs·2025
Same author

Clesrovimab: First Approval.

Drugs·2025
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
查看所有相关文章

相关实验视频

Updated: Jan 15, 2026

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.7K

Lisaftoclax:第一次批准

Yahiya Y Syed1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|October 8, 2025
PubMed
概括
此摘要是机器生成的。

一种B细胞淋巴瘤2 (BCL-2) 抑制剂Lisaftoclax在中国首次获得批准,用于治疗慢性淋巴细胞白血病 (CLL) 和小淋巴细胞淋巴瘤 (SLL). 这标志着血液恶性瘤治疗的重要里程碑.

更多相关视频

Measuring Influenza Neuraminidase Inhibition Antibody Titers by Enzyme-linked Lectin Assay
08:11

Measuring Influenza Neuraminidase Inhibition Antibody Titers by Enzyme-linked Lectin Assay

Published on: September 6, 2016

19.6K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.9K

相关实验视频

Last Updated: Jan 15, 2026

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.7K
Measuring Influenza Neuraminidase Inhibition Antibody Titers by Enzyme-linked Lectin Assay
08:11

Measuring Influenza Neuraminidase Inhibition Antibody Titers by Enzyme-linked Lectin Assay

Published on: September 6, 2016

19.6K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.9K

科学领域:

  • 在瘤学瘤学.
  • 药理学 药理学是指药理学的学科.
  • 血液学 血液学 血液学

背景情况:

  • 利萨夫托克拉克斯是一种新型B细胞淋巴瘤2 (BCL-2) 抑制剂,用于血液恶性瘤.
  • 它通过5天的升级剂量计划进行管理,在第6天达到目标剂量.
  • 该药物向BCL-2,这是一种涉及癌细胞存活的蛋白质.

研究的目的:

  • 要总结 lisaftoclax 的关键发展里程碑.
  • 详细说明通往其首次监管批准的道路.
  • 为了突出该药物针对特定血液癌症的初始适用性.

主要方法:

  • 对 lisaftoclax.clinical 的临床前和临床发展数据的审查.
  • 对监管提交和批准流程的分析.
  • 临床试验结果的摘要与已批准的适用情况相关.

主要成果:

  • 利萨夫托克拉克斯在2025年7月10日在中国获得了首次批准.
  • 批准适用于患有慢性淋巴细胞白血病 (CLL) 或小淋巴细胞淋巴瘤 (SLL) 的成年患者.
  • 患者必须至少接受过一次先前的全身疗法,包括布鲁顿的氨酸激酶 (BTK) 抑制剂.

结论:

  • 利萨夫托克拉克斯的批准代表了治疗复发性/耐药性CLL/SLL的重大进展.
  • 这一里程碑验证了BCL-2抑制在血液癌症中的治疗潜力.
  • 预计将在其他血液性恶性瘤中进一步开发和探索lisaftoclax.